Interim results of a multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).

被引：3

作者：

Lacy, Jill

Portales, Fabienne

Hammel, Pascal

Cid, Roberto A. Pazo

Mozo, Jose Luis Manzano

Kim, Edward Jae-hoon

Dowden, Scot D.

Borg, Christophe

Sastre, Javier

Bathini, Venu Gopal

Terrebonne, Eric

Lopez-Trabada, Daniel

Rivera, Fernando

Asselah, Jamil

Damiani, Azzurra

Hwang, Jimmy J.

Ong, Teng Jin

Nydam, Thom

Li, Jack Shiansong

Philip, Philip Agop

机构：

[1] Yale Canc Ctr, New Haven, CT USA

[2] Inst Reg Canc Montpellier ICM, Montpellier, France

[3] Hop Beaujon, Clichy, France

[4] Hosp Miguel Servet, Zaragoza, Spain

[5] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

[6] UC Davis Comprehens Canc Ctr, Sacramento, CA USA

[7] Tom Baker Canc Clin, Calgary, AB, Canada

[8] Ctr Hosp Belfort Montbeliard, Montbeliard, France

[9] Hosp Clin San Carlos, Madrid, Spain

[10] Univ Massachusetts, Sch Med, Canc Ctr Excellence, Worcester, MA USA

[11] Hop Haut Leveque, Giround, France

[12] Hop St Antoine, Paris, France

[13] Hosp Univ Marques de Valdecilla, Santander, Spain

[14] McGill Univ, Royal Inst, Montreal, PQ, Canada

[15] Azienda Osped Univ San Martino, Genoa, Italy

[16] Georgetown Univ, Dept Med & Oncol, Lombardi Comprehens Canc Ctr, Washington, DC USA

[17] Georgetown Univ, Innovat Ctr Biomed Informat, Lombardi Comprehens Canc Ctr, Washington, DC USA

[18] Celgene Corp, Summit, NJ USA

[19] Karmanos Canc Ctr, Detroit, MI USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷 / 04期

关键词：

D O I：

10.1200/JCO.2017.35.4_suppl.358

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

358

引用

页数：1

共 50 条

[31] APACT: a Phase III Trial of nab-Paclitaxel (nab-P) Plus Gemcitabine (Gem) vs Gem Alone as Adjuvant Therapy for Patients (pts) with Resected Pancreatic Cancer (PC)
Tempero, M. A.
Cardin, D.
Biankin, A.
Goldstein, D.
Moore, M.
O'Reilly, E. M.
Philip, P.
Riess, H.
Macarulla, T.
Yung, L.
Wei, X.
Lu, B.
PANCREAS, 2014, 43 (08) : 1416 - 1416
[32] Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
Akiko Tsujimoto
Kentaro Sudo
Kazuyoshi Nakamura
Emiri Kita
Ryusuke Hara
Wataru Takayama
Hiroshi Ishii
Taketo Yamaguchi
Scientific Reports, 9
[33] Analysis of prognostic factors in advanced pancreatic cancer (APDAC) patients (pts) undergoing to first-line nab-paclitaxel (Nab-P) and gemcitabine (G) treatment
Giordano, Guido
Vaccaro, Vanja
Lucchini, Eleonora
Bertocchi, Paola
Bergamo, Francesca
Musettini, Gianna
Santoni, Matteo
Lo Re, Giovanni
Giommoni, Elisa
Russano, Marco
Campidoglio, Serena
Santini, Daniele
Vasile, Enrico
Cascinu, Stefano
Zagonel, Vittorina
Zaniboni, Alberto
Melisi, Davide
Milella, Michele
Febbraro, Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[34] Reinitiating nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer
Borazanci, Erkut
Schroeder, Katy
Jameson, Gayle S.
Ramanathan, Ramesh K.
Von Hoff, Daniel D.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
[35] A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC)
Hidalgo, M.
Pazo-Cid, R.
Guillen-Ponce, C.
Lopez, R.
Vera, R.
Reboredo, M.
Munoz, A.
Martinez de Castro, E.
Diaz Beveridge, R.
La Casta, A.
Martin-Valades, J. I.
Cubillo, A.
Martinez-Galan, J.
Ales, I.
Sastre, J.
Macarulla Mercade, T.
ANNALS OF ONCOLOGY, 2017, 28
[36] SPARC microenvironment signature (SMS) analysis of a phase II trial of neoadjuvant gemcitabine (G), epirubicin (E), and nab-paclitaxel (nab-P) in locally advanced breast cancer (LABC)
Yardley, D. A.
Daniel, B. R.
Inhorn, R. C.
Vazquez, E. R.
Trieu, V. N.
Motamed, K.
Hwang, L.
Rugo, H. S.
Desai, N.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[37] Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).
Moore, Malcolm J.
Von Hoff, Daniel D.
Ervin, Thomas J.
Arena, Francis P.
Chiorean, E. Gabriela
Infante, Jeffrey R.
Hon, Jeremy K.
Biakhov, Mikhail Yu
Hingorani, Sunil R.
Ganju, Vinod
Weekes, Colin D.
Scheithauer, Werner
Ramanathan, Ramesh K.
Tabernero, Josep
Goldstein, David
Wei, Xinyu
Romano, Alfredo
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[38] Phase II clinical trial of nab-paclitaxel plus cisplatin plus gemcitabine (NABPLAGEM) in patients with untreated advanced pancreatic cancer
Jameson, Gayle S.
Hosein, Peter J.
Pierce, Erin
Kamgar, Mandana
Gordon, Michael S.
Snyder, Courtney
Roe, Denise J.
Wertheim, Betsy C.
Davey, Marina
Barrett, Michael T.
Von Hoff, Daniel D.
Borazanci, Erkut
CANCER MEDICINE, 2024, 13 (12):
[39] APACT: Phase III randomized trial of adjuvant treatment with nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with resected pancreatic cancer (PC).
Tempero, Margaret A.
Cardin, Dana Backlund
Goldstein, David
O'Reilly, Eileen Mary
Philip, Agop Philip
Riess, Hanno
Macarulla, Teresa
Yung, Lotus
Li, Mingyu
Lu, Brian D.
Biankin, Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
[40] A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer
Kobayashi, Satoshi
Ueno, Makoto
Ikeda, Masafumi
Ozaka, Masato
Sano, Yusuke
Hirotani, Akane
Tozuka, Yuichiro
Fukushima, Taito
Tezuka, Shun
Moriya, Satoshi
Umemoto, Kumiko
Watanabe, Kazuo
Sasaki, Mitsuhito
Hashimoto, Yusuke
Imaoka, Hiroshi
Ohno, Izumi
Mitsunaga, Shuichi
Yamada, Ikuhiro
Sasaki, Takashi
Sasahira, Naoki
Morimoto, Manabu
PANCREAS, 2020, 49 (02) : 187 - 192

← 1 2 3 4 5 →